WS Investor
14 Sep 2026, 16:59
Johnson & Johnson’s RYBREVANT Combination Extends Median Survival in Advanced Lung Cancer Study
Johnson & Johnson reported final Phase 3 data showing that RYBREVANT combined with chemotherapy achieved a median overall survival of 34.3 months in patients with advanced non-small cell lung cancer carrying EGFR exon 20 insertion mutations, compared with 27.9 months for chemotherapy alone.
The PAPILLON study evaluated first-line RYBREVANT plus carboplatin-pemetrexed against chemotherapy alone. Johnson & Johnson said the combination extended median survival by more than six months despite 76% of eligible patients in the chemotherapy group later crossing over to RYBREVANT after their disease progressed.
In the protocol-specified final analysis, the overall-survival hazard ratio was 0.87 and the result was not statistically significant. However, a prespecified analysis adjusting for crossover showed a 43% reduction in the risk of death, with a hazard ratio of 0.57 and nominal P value of 0.003. The treatment also extended progression-free survival through second disease progression to 28.3 months from 17.5 months.
The results are significant for a difficult-to-treat form of lung cancer. EGFR exon 20 insertion mutations account for roughly 12% of EGFR mutations and historically have been associated with median overall survival of about 16–24 months and a five-year survival rate of just 8%.
RYBREVANT is a bispecific antibody designed to target both EGFR and MET, pathways involved in tumor growth and treatment resistance. The latest results strengthen Johnson & Johnson’s clinical evidence for the therapy in EGFR-mutated lung cancer.
Johnson & Johnson reported final Phase 3 data showing that RYBREVANT combined with chemotherapy achieved a median overall survival of 34.3 months in patients with advanced non-small cell lung cancer carrying EGFR exon 20 insertion mutations, compared with 27.9 months for chemotherapy alone.
The PAPILLON study evaluated first-line RYBREVANT plus carboplatin-pemetrexed against chemotherapy alone. Johnson & Johnson said the combination extended median survival by more than six months despite 76% of eligible patients in the chemotherapy group later crossing over to RYBREVANT after their disease progressed.
In the protocol-specified final analysis, the overall-survival hazard ratio was 0.87 and the result was not statistically significant. However, a prespecified analysis adjusting for crossover showed a 43% reduction in the risk of death, with a hazard ratio of 0.57 and nominal P value of 0.003. The treatment also extended progression-free survival through second disease progression to 28.3 months from 17.5 months.
The results are significant for a difficult-to-treat form of lung cancer. EGFR exon 20 insertion mutations account for roughly 12% of EGFR mutations and historically have been associated with median overall survival of about 16–24 months and a five-year survival rate of just 8%.
RYBREVANT is a bispecific antibody designed to target both EGFR and MET, pathways involved in tumor growth and treatment resistance. The latest results strengthen Johnson & Johnson’s clinical evidence for the therapy in EGFR-mutated lung cancer.
